Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Blood (2021) 137 (20): 2838–2847.

https://doi.org/10.1182/blood.2020010529

Published: 2021

Includes: Supplemental data

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Muhammad Zain Farooq, MD MBBS, Prasanth Lingamaneni, Saira Farid, MD, Muhammad Saad Farooq, MBBS, Ishaan Vohra, MD, Asim Tameez ud din, MD, Ankit Mangla, MBBS,MD

Blood (2019) 134 (Supplement_1): 3465.

https://doi.org/10.1182/blood-2019-132151

Published: 2019

Journal Articles

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Nefeli Giannakopoulou, Marianna Politou, MD, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitris Korakakis, Maria Efstathopoulou, Theodora Kassi, Christina-Nefeli Kontandreopoulou, Katerina Zoi, PhD, Andreas Giannopoulos, BSc, MSc, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou, MD

Blood (2018) 132 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2018-99-116660

Published: 2018

Journal Articles

Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis

Blood (2018) 132 (Supplement 1): 458.

https://doi.org/10.1182/blood-2018-99-119182

Published: 2018

Journal Articles

Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study

Blood (2018) 132 (Supplement 1): 750.

https://doi.org/10.1182/blood-2018-99-114717

Published: 2018

Journal Articles

Arterial Thrombotic Events in CML Patients Treated with First-Line Nilotinib: Incidence, Management and Impact on the Long Term Outcome — a Gimema CML WP Analysis

Blood (2017) 130 (Supplement 1): 1625.

https://doi.org/10.1182/blood.V130.Suppl_1.1625.1625

Published: 2017

Journal Articles

Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party

Blood (2016) 128 (22): 3068.

https://doi.org/10.1182/blood.V128.22.3068.3068

Published: 2016

Journal Articles

Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular Responses

Brendan Wisniowski, MBBS, Sally Mapp, MBBS, PhD FRACP, FRCPA, Louise Knop, BSc (Hons), James Morton, MBBS, BSc(MD, FRACP, FRCPA, Paul Eliadis, FRACP,FRCPA,MBBS, Anthony K. Mills, MBBS, FRACP, FRCPA

Blood (2016) 128 (22): 5460.

https://doi.org/10.1182/blood.V128.22.5460.5460

Published: 2016

Journal Articles

Bernaudin F, Verlhac S, Arnaud C, et al. Chronic acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125(10): 1653-1661 .

Blood (2015) 125 (17): 2736.

https://doi.org/10.1182/blood-2015-03-634063

Published: 2015

Journal Articles

Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia

Françoise Bernaudin, Suzanne Verlhac, Cécile Arnaud, Annie Kamdem, Manuela Vasile, Florence Kasbi, Isabelle Hau, Fouad Madhi, Christine Fourmaux, Sandra Biscardi, Ralph Epaud, Corinne Pondarré

Blood (2015) 125 (10): 1653–1661.

https://doi.org/10.1182/blood-2014-09-599852

Published: 2015

Journal Articles

A 10 Year Retrospective Analysis of Carotid Stenosis in Patients with Polycythemia Vera or Essential Thrombocythemia

Arun Nagarajan, MD, Rahul Lanka, Aravinda Nanjundappa, MD, Stephanie Thompson, PhD

Blood (2014) 124 (21): 5554.

https://doi.org/10.1182/blood.V124.21.5554.5554

Published: 2014

Journal Articles

Zymogen-like FXa Is a Potent Bypassing Agent for Reversal of Direct FXa Inhibitors in Vivo

Nabil K. Thalji, BS, Lacramioara Ivanciu, PhD, Reema Jasuja, Sunita Patel-Hett, PhD, Joachim Fruebis, PhD, Debra Pittman, Rodney M. Camire, PhD

Blood (2014) 124 (21): 582.

https://doi.org/10.1182/blood.V124.21.582.582

Published: 2014

Journal Articles

Thrombosis Protection In Klkb1 -/- (Prekallikrein KO) Mice Is Mediated By Increased Renal Mas Receptor, Plasma Prostacyclin, and Aortic Sirt1

Chao Fang, Evi Stavrou, MD, Yunmei Wang, PhD, Nadja Grobe, PhD, Daniel I. Simon, MD, Alvin H. Schmaier, MD

Blood (2013) 122 (21): 195.

https://doi.org/10.1182/blood.V122.21.195.195

Published: 2013

Journal Articles

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

Wilfried Auer, PhD, Hanspeter Rottensteiner, PhD, Gerald Schrenk, PhD, Werner Hoellriegl, PhD, Alexandra Schiviz, DVM, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Peter L Turecek, PhD, Eva-Maria Muchitsch, PhD

Blood (2012) 120 (21): 2233.

https://doi.org/10.1182/blood.V120.21.2233.2233

Published: 2012

Journal Articles

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Alexandra Schiviz, Eder Barbara, John-Philip Lawo, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, Werner Hoellriegl

Blood (2011) 118 (21): 4350.

https://doi.org/10.1182/blood.V118.21.4350.4350

Published: 2011

Journal Articles

Silent Brain Abnormalities in Thalassemia Intermedia: A Combined MRI/PET Study.

Ali Taher, Khaled Musallam, Wassim Nasreddine, Ahmad Beydoun

Blood (2009) 114 (22): 4077.

https://doi.org/10.1182/blood.V114.22.4077.4077

Published: 2009

Journal Articles

Phenotypic Correction of Adamts13 -Deficient Mice by Early Intra-Amniotic Gene Transfer of Lentiviral Vector Encoding ADAMTS13 Genes.

Masami Niiya, MD, PhD, Masayuki Endo, MD/PhD, Philip W. Zoltick, MD, Nidal E. Muvarak, David G. Motto, MD/PhD, Alan W. Flake, MD, X. Long Zheng, MD/PhD

Blood (2007) 110 (11): 197.

https://doi.org/10.1182/blood.V110.11.197.197

Published: 2007

Journal Articles

Framingham Score in Congenital Hemophilia Patients (HP) with Cardiovascular Disease (CVD).

Rekha Parameswaran, MD, Anne Greist, MD, Lorrie Miller-Rice, MD, Chris Roberson, Renee Murry, Matthew Sulkin, Henry Lynn, Amy Shapiro, MD

Blood (2005) 106 (11): 320.

https://doi.org/10.1182/blood.V106.11.320.320

Published: 2005

Journal Articles

Marburg I polymorphism of factor VII–activating protease is associated with idiopathic venous thromboembolism

Berthold Hoppe, Farzaneh Tolou, Hartmut Radtke, Holger Kiesewetter, Thomas Dörner, Abdulgabar Salama

Blood (2005) 105 (4): 1549–1551.

https://doi.org/10.1182/blood-2004-08-3328

Published: 2005

NARROW

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis

Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study

Arterial Thrombotic Events in CML Patients Treated with First-Line Nilotinib: Incidence, Management and Impact on the Long Term Outcome — a Gimema CML WP Analysis

Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party

Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular Responses

Bernaudin F, Verlhac S, Arnaud C, et al. Chronic acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125(10): 1653-1661 .

Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia

A 10 Year Retrospective Analysis of Carotid Stenosis in Patients with Polycythemia Vera or Essential Thrombocythemia

Zymogen-like FXa Is a Potent Bypassing Agent for Reversal of Direct FXa Inhibitors in Vivo

Thrombosis Protection In Klkb1 -/- (Prekallikrein KO) Mice Is Mediated By Increased Renal Mas Receptor, Plasma Prostacyclin, and Aortic Sirt1

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Silent Brain Abnormalities in Thalassemia Intermedia: A Combined MRI/PET Study.

Phenotypic Correction of Adamts13 -Deficient Mice by Early Intra-Amniotic Gene Transfer of Lentiviral Vector Encoding ADAMTS13 Genes.

Framingham Score in Congenital Hemophilia Patients (HP) with Cardiovascular Disease (CVD).

Marburg I polymorphism of factor VII–activating protease is associated with idiopathic venous thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only